Zimbabwe has declined a major US health deal valued at $367m (£272m) over five years over the United States' insistence on sensitive biological samples.
This move was revealed following a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson has since explained that the US was requesting health data for research and profit but was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more dialogue to find a deal suitable to both sides so the nation's critical HIV programme can proceed.
Broader Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court halted a related deal with the US after concerns were filed about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the US government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and accountability.
According to reports, Sixteen African countries have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would provide the raw materials for medical research with no certainty that the end products would be accessible to our people should a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining systems already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This system is intended to ensure that when a country contributes its data, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future co-operation might be designed in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that negotiations need to persist given that a large portion of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns arise, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," the group added.
This impasse underscores the ongoing challenges between accepting vital international aid and protecting national sovereignty in an increasingly interconnected world.